IP Library Granted Patent US 7,368,107
Granted Patent B2
US 7,368,107 · App. 11/227,238 · Granted May 6, 2008

Tumor antigen peptides derived from cyclophilin B

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,368,107
App. No.
11/227,238
Granted
May 6, 2008
Kind
B2
Abstract

Tumor antigen peptides derived from cyclophilins or derivatives thereof having the functionally equivalent properties; medicaments, prophylactics, or diagnostics for tumors comprising as an active ingredient such tumor antigen peptides or derivatives thereof, cyclophilins or partial polypeptides thereof, or genes encoding said cyclophilins or partial polypeptides thereof; in vitro use of the above substances for treatment of tumors; and antibodies against the above tumor antigen peptides derived from cyclophilins or derivatives thereof are provided.

Claims (4)

1. An isolated dendritic cell wherein a complex between an HLA-A24 antigen and a tumor antigen peptide consisting of a sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID: NO 2, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, and SEQ ID NO: 43, is presented on the surface.

2. The dendritic cell of claim 1 in which the HLA-A24 antigen-tumor antigen peptide complex is recognized by a cytotoxic T lymphocyte.

3. A composition comprising the dendritic cell of claim 1 .

4. A composition comprising the dendritic cell of claim 2 .

Assignments (1)
MERGER Recorded Dec 16, 2005
From: SUMITOMO PHARMACEUTICALS COMPANY, LTD.
To: DAINIPPON SUMITOMO PHARMA CO., LTD.
Reel/Frame 017089/0420 →